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Background: To study the management  pattern 
of soft tissue sarcomas in a tertiary care setting   
Methods:  In this descriptive study patients who 
were operated for soft tissue masses were included. 
Intra-operative findings, procedure details and 
postoperative orders were recorded. Postoperative 
chemo-radiotherapy records were reviewed and 
recorded.   Depth of the tumour was grouped as 
deeper or superficial than 5 cm.  The follow up 
records were accessed from the outpatient 
department and any surgical complications were 
recorded up to three years.Staging was done using 
clinical and radiological criteria taking into account 
the histological grade,tumour size , depth, local 
lymph node invasion and metastasis.Surgical 
procedure for removal of STS are wide local excision 
(WLE), intralesional excision (IE) or tumor 
debulking, marginal excision (ME) and radical 
excision (RE).   
Results: Sixty eight patients with mean age of 43.0 
± 17.258 SD were diagnosed as cases of soft tissue 
sarcomas. Male to female ratio was 3.25:1.The most 
common histopathological variety was malignant 
fibrous histiocytoma (35.3%) , followed by 
Rhabdomyosarcoma(30%).  Most  common involved 
site was lower limbs (35.3%).Wide local excision was 
performed in majority (82.4%) . Most common 
postop complication was wound infection (10.3%) 
Conclusion: Clinicians must be agile about the 
nature of these tumours and their referral to a 
specialist surgeon for further management. Prompt 
diagnosis, accurate investigations and early 
intervention will benefit the patients and help us 
understand this disease entity. 
Key Words: Soft tissue sarcoma, Surgical 
oncology, Multidisciplinary management 
  
Introduction 
Soft tissue sarcomas are rare tumours with a 
prevalence of only 1% among all the diagnosed 
malignancies. The low prevalence of these tumours 
has predictably resulted into less experience of 
primary healthcare physicians and surgeons about 
their management with consequent errors in diagnosis, 
treatment delays and reporting. Advances in 
molecular biology, oncogenetics, techniques of modern 
imaging, histopathological techniques, 
immunochemistry, good surgical care and chemo-
radiotherapy have led us to better understand these 
rare mesenchymal tumours, commonly known as soft 
tissue sarcomas (STS).1-3 
Almost 40 years ago, surgical resection was deemed as 
the only therapeutic intervention for STS which in high 
grade tumours resulted in poorer prognosis and 
shorter survival rates. Good investigative techniques, 
higher clinical vigilance with pre- and post-operative 
radiation and chemotherapy has helped increase long-
term survival and reduced morbidity in patients of 
these rare tumours.4-6 
Although STS comprise almost 1% of the total cancer 
diagnoses, due to its insidious nature and apparently 
non-alarming initial clinical appearance it causes 
significant morbidity and mortality, especially in the 
young age groups.7 A majority of patients present late 
due to initial misdiagnosis by the primary care 
physician or locally available surgeon who happen to 
least suspect a soft tissue mass as being malignant. The 
diverse variety of histopathologic nature of these 
tumours can be reflected by the fact that there are 
more than 40 different subtypes of adult STS and 
similar number of STS subtypes in paediatric age 
groups. Survival estimates still depends upon the 
individual histopathological diagnosis and ranges 
from 92% to 19%.8,9 
A multidisciplinary team approach especially with 
dedicated STS teams is the best method which can 
benefit patients in terms of lower morbidity and 
improved survival.10-12 Similarly, intraoperative 
radiotherapy, pre-operative chemo-radiotherapy and 
the use of modern imaging techniques in order to 
monitor long term outcome and relapse rate are the 
tools which could be the key to success.13-15 
 
Methods 
After the Hospital Ethical Committee’s approval, the 
study was conducted at the General Surgery Unit II of 
Journal of Rawalpindi Medical College (JRMC); 2018;22(1): 58-62 
 59 
Pakistan Institute of Medical Sciences Islamabad. In 
this descriptive study all patients, between the ages of 
14 years to 85 years of age, who were operated for soft 
tissue masses were included. Preoperative 
investigative studies such as CT, MRI and fine needle 
aspiration cytology reports were recorded. Intra-
operative findings, procedure details and 
postoperative orders were recorded. Postoperative 
chemo-radiotherapy records were reviewed and 
recorded.   Size  and  depth of the tumour  and 
structures invaded or compressed by the tumour was 
assessed using the radiology. Size of the tumour was 
grouped as smaller or larger than 5 cm. Depth of the 
tumour was grouped as deeper or superficial than 5 
cm. Patients were consented after full discussion of the 
pros and cons of the procedure and the need for 
postoperative radio-oncology and general surgery 
follow up were preoperatively discussed with them. 
Those patients who were clearly labelled as having 
malignant tumours on FNA reports were also referred 
to the oncologist for receiving preoperative chemo-
radiotherapy. The follow up records were accessed 
from the outpatient department and any surgical 
complications were recorded up to three years.Staging 
was done using clinical and radiological criteria taking 
into account the histological grade (G1: well 
differentiated, G2: moderately well differentiated and 
G3 & G4: poorly differentiated, undifferentiated), 
tumour size (smaller or larger than 5 cm in greatest 
dimension), depth (deeper more or less than 5 cm), 
local lymph node invasion (N0: no lymph nodes, N1: 
lymph nodes positive) and metastasis (M0: no 
metastasis, M1: metastasis positive).16Surgical 
procedure for removal of STS are wide local excision 
(WLE), intralesional excision (IE) or tumor debulking, 
marginal excision (ME) and radical excision (RE). The 
need for a particular surgical procedure was 
determined according to clinical findings and 
radiological evaluation.Paediatric patients, recurrent 
cases, non-operable cases and tumours with clearly 
benign clinical and histological findings were excluded 
from the study. 
  
Results 
Out of sixty eight patients 76.5% were  male and 23.5% 
were  female. Mean age was 43 years ± 17.358 SD 
(range = 14-85). (Table 1). The most common diagnosis 
was  of malignant fibrous histiocytoma (MFH) (35.3%), 
was followed by rhabdomyosarcoma (17.6%) and 
liposarcoma (3.2%). (Table 2).Lower extremity(35.35), 
especially gluteal and thigh are, was the most frequent 
site involved  (Table 3).Forty nine (72.1%) cases were 
larger than 5 cm while 27.9% cases were smaller 
tumours (size < 5 cm). Thirty six (52.9%) tumours were 
classified as superficial (tumour depth < 5 cm). Forty  
(58.8%) of tumours had radiological evidence of 
invasion of the local structures while 8 (11.8%) cases 
were encountered with metastasis to other regions of 
the body (most commonly lungs and liver). Twenty 
(29.4%) cases  were well differentiated tumours (G1) 
(Table 4). Preoperative oncological treatment was 
given only in 5 (7.4%) cases while 35 (51.5%) patients 
received postoperative oncology treatment. Resection 
margins were positive in 14 (20.6%) specimens after 
histopathological review.Wide local excision was 
performed in majority ( 82.4%) (Table 5). Postoperative 
complications occurred in 39.7% . (Table 6) 
 
Table 1: Age groups distribution 
Age Group No Percentage  
1 (14-25 years) 14 20.6 
2 (26-40 years) 17 25.0 
3 (41-55 years) 21 30.9 
4 (56-70 years) 13 19.1 
5 (71-85 years) 3 4.4 
Mean Age: 43 ± 17.358 SD 
 
Table 2: Tumour subtypes and their frequencies 
Tumour Subtype Number Percentage  
MalignantFibrousHistiocytoma 24 35.3 
Rhabdomyosarcoma 12 17.6 
Liposarcoma 9 13.2 
Fibrosarcoma 8 11.8 
Synovial Sarcoma 4 5.9 
Ewing's Sarcoma 3 4.4 
Leiyomyosarcoma 3 4.4 
Schwannoma 2 2.9 
Angiosarcoma 1 1.5 
Dermatofibroma 1 1.5 
Neurofibroma 1 1.5 
 
Table 3: Body sites and tumour frequencies 
Body Site Number Percentage 
Lower Extremity 24 35.3 
Upper Extremity 14 20.6 
Intra-abdominal 13 19.1 
Trunk 10 14.7 
Retroperitoneal 4 5.9 
Head and Neck 2 2.9 
Intrathoracic 1 1.5 
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Table 4: Tumour staging and their occurrence 
Tumour Stage Frequency  Percentage  
Stage 1a 14 20.6 
Stage 1b 19 27.9 
Stage 2a 7 10.3 
Stage 2b 7 10.3 
Stage 2c 12 17.6 
Stage 3 6 8.8 
Stage 4 3 4.4 
Table 5 : Surgical procedures in the study 
Surgical  procedure No(%) 
Wide local excision 56 (82.4) 
Radical excision 7(10.3) 
Marginal resection  3 (4.4) 
Intralesional resection  2 (2.9) 
Table 6: Postoperative complications 
Complications Frequency  Percentage 
Wound infection 7 10.3% 
Subcutaneous Seroma 6 8.8% 
Bleed / Haematoma 3 4.4% 
Wound Dehiscence 3 4.4% 
Flap necrosis 3 4.4% 
Local Muscle Paralysis 2 2.9% 
Tumour Bed Abscess 1 1.5% 
Pleural Effusion 1 1.5% 
Postop Pneumothorax 1 1.5% 
 
Discussion 
Soft tissue sarcomas are heterogeneous tumours of 
mesenchymal multipotent stem cells origin with 
insidious onset and no specific set of symptoms or 
signs. Most of the tumours present with localised 
swellings, pressure effects or symptoms due to 
invasion of body organs or structures. In most cases 
before the patient reaches the tertiary care clinics, 
opinion from locally available primary physicians has 
already been sought. In such situations, diagnostic 
delay, misdiagnosis and consequent mistreatment 
always lead to delayed presentation or presenting with 
complications of the disease.17-19 
Modern imaging techniques, histopathological 
advancements and novel techniques of the 
immunohistochemistry and oncogenetics have enabled 
the modern oncological research to identify more than 
50 different types of adult STS.20-22In Pakistan 
however, the newly available diagnostic techniques, 
histopathology services and more importantly 
expertise in the field of soft tissue neoplasm 
management is a scarcity.23 Most reports have cited the 
data available from tertiary care centres and 
epidemiological studies.24 The need of the moment is 
to enhance the surgical research on planned 
techniques of excision, repair and postoperative care of 
this subset of patients.25 
As emphasized by Umar HM et al planned excision is 
the only approach which appear feasible for 
controlling local recurrence and disease spread.24 
Although several authors have shown that local 
recurrence is not significantly associated with 
unplanned excision,26 others have demonstrated the 
efficacy of planned excision of a STS in order to reduce 
the risk of local recurrence.18,24,27 Though we did not 
include data about local recurrence of the primary 
tumours in our study, surgical outcome studies have 
included this aspect as viable to study overall survival 
as well as morbidity free interval and is the standard 
of care in all soft tissue sarcoma care centres.24,27,28 
Another important aspect of proper referral for 
sarcoma patients is that surgical excision increasingly 
becomes difficult, intraoperative complications, 
wound complications and the risk of tumour seeding 
in neighbouring tissues become high.24,27 Obtaining a 
negative surgical margin is another factor which 
becomes difficult in recurrent disease and in those 
cases with very large tumours, both related to delayed 
diagnosis or improper treatment. Liu C et al has 
described a surgical margin of at least 10 mm for good 
postoperative outcome and good control of local 
recurrence.29 The goal of our surgical planning in these 
cases was to obtain a negative margin of at least 2 cm. 
However, the 8 cases of grade 3 & 4 disease and 6 from 
the stage 2c patients were found to have a positive 
margin on histopathology review of the specimen. 
Liposarcoma and synovial sarcoma were the most 
common tumours which affected the surgical margins 
clearance. 
Opinion, attitude towards new practices and expertise 
of the sarcoma treating physician, surgeon or 
oncologist is of paramount importance which 
determines the efficacy of the pre- or post-operative 
treatment. Treatment preferences among various 
specialty physicians regarding neoadjuvant 
radiotherapy and chemotherapy were highly variable 
and was influenced by specialty and clinical 
experience of the physician.28 
In our study majority of patients were male (76.5%) 
with mean age of 43.0 years ± 17.358, while malignant 
fibrous histiocytoma was the predominant subtype of 
tumour encountered (35.3%). Similarly, the most 
commonly encountered body site were the extremities 
(55.9%) followed by intra-abdominal tumours (25.0%). 
Some of the findings about age distribution are 
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concurrent with the studies of Bhurgri Y et al and 
Qadir I et al where average age was 40.5 years and 
41.8 years respectively with a majority of male 
patient.23,30 In the study by Bhurgri Y et al, 
Rhabdomyosarcoma accounted for 22.2% tumours and 
the most abundant one.30 However, in the study by 
Qadir I et al, the predominant tumour type was 
synovial sarcoma and leiyomyosarcoma (36.1%) as 
compared to our study (MFH: 35.3%; 
Rhabdomyosarcoma: 17.6%; Synovial sarcoma: 
5.9%).23 Despite the scarcity of resources for 
widespread multimodality treatment facilities in 
Pakistan, Qadir I et al have shown that our local 
recurrence and overall survival rates are comparable 
to the developed countries.23 This is a quite 
encouraging finding for our cancer research 
community and broadly for our healthcare 
community. 
The most common method of preoperative tissue 
diagnosis in our cohort of STS patients was the 
utilisation of fine needle aspiration coupled with 
contrast enhanced CT/MRI. Specific cytological and 
radiological markers of malignancy are important in 
this regard as discussed by Ahmed Z et al in 
elucidating the importance of histopathology and 
immune-histochemistry.31 As is pointed by 
Chintamani, the most important factor in diagnostic 
difficulty of STSs is their histologic heterogeneity, 
which has also hampered the treatment advancement 
for years.32Data regarding follow-up once the patient 
left for postoperative oncology treatment, recurrence 
and disease free or overall survival rates are necessary 
for evaluating the patients suffering from STS and the 
success or failure of a particular modality of treatment. 
These limitations can be avoided by designing proper 
long-term prospective studies with survival and 
recurrence assessment. More important though, is the 
formation of multimodality treatment boards in order 
to treat this subset of patients. 
 
Conclusion 
1.In the management of soft tissue sarcomas increased 
vigilance, regarding preoperative workup, and proper 
referral are of paramount importance.  
2.Preoperative oncological treatment and  planned 
excision needs emphasis. Multimodality surgical and 
oncological support in tertiary care centres can be 
translated into increased survival and improved 
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